SG10201808863UA - Combined chemical and genetic approaches for generation of induced pluripotent stem cells - Google Patents

Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Info

Publication number
SG10201808863UA
SG10201808863UA SG10201808863UA SG10201808863UA SG10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA SG 10201808863U A SG10201808863U A SG 10201808863UA
Authority
SG
Singapore
Prior art keywords
generation
stem cells
pluripotent stem
induced pluripotent
genetic approaches
Prior art date
Application number
SG10201808863UA
Inventor
Yan Shi
Caroline Desponts
Sheng Ding
Hongyan Zhou
Tongxiang Lin
Wenlin Li
Saiyong Zhu
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG10201808863UA publication Critical patent/SG10201808863UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
    • C12N2506/094—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells from keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency. [Figure ] 82
SG10201808863UA 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells SG10201808863UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6995608P 2008-03-17 2008-03-17
US19798608P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
SG10201808863UA true SG10201808863UA (en) 2018-11-29

Family

ID=41091504

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201808863UA SG10201808863UA (en) 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG2013019211A SG188904A1 (en) 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG10201607710UA SG10201607710UA (en) 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG10202103401QA SG10202103401QA (en) 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG2013019211A SG188904A1 (en) 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG10201607710UA SG10201607710UA (en) 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG10202103401QA SG10202103401QA (en) 2008-03-17 2009-03-17 Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Country Status (16)

Country Link
US (8) US9534205B2 (en)
EP (3) EP2279243B1 (en)
JP (6) JP5951254B2 (en)
KR (1) KR101679082B1 (en)
CN (2) CN102027105B (en)
AU (1) AU2009225665B9 (en)
BR (1) BRPI0908708A2 (en)
CA (1) CA2718904C (en)
ES (1) ES2690554T3 (en)
HK (2) HK1151559A1 (en)
IL (1) IL208144B (en)
MX (1) MX2010010165A (en)
RU (1) RU2010139426A (en)
SG (4) SG10201808863UA (en)
WO (1) WO2009117439A2 (en)
ZA (1) ZA201006683B (en)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171185A1 (en) * 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
ES2836764T3 (en) 2005-08-03 2021-06-28 Astellas Inst For Regenerative Medicine Improved methods of reprogramming animal somatic cells
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
BRPI0619794B8 (en) * 2005-12-13 2022-06-14 Univ Kyoto Use of a reprogramming factor, agent for preparing an induced pluripotent stem cell from a somatic cell and methods for preparing an induced pluripotent stem cell method and for preparing a somatic cell and use of induced pluripotent stem cells
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
JP2010523117A (en) 2007-04-07 2010-07-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Somatic cell reprogramming
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US20140342984A1 (en) * 2007-10-19 2014-11-20 Robert G. Matheny Compositions for Regenerating Defective or Absent Myocardium
BRPI0908708A2 (en) 2008-03-17 2019-09-24 Scripps Research Inst methods for producing pluripotent stem cells induced from non-pluripotent mammalian cells, to screen for agents that induce reprogramming or de-differentiation of mammalian cells within pluripotent stem cells, to screen for mammalian cells with pluripotent stem cell characteristics , to induce oct4 expression in a cell and to induce non-pluripotent cells in pluripotent cells, mixing, mammalian cell, methods for producing pluripotent stem cells induced from non-pluripotent mammalian cells, to screen for agents that induce reprogramming or de-differentiating mammalian cells within pluripotent stem cells, to screen for mammalian cells with pluripotent stem cell characteristics, to induce oct4 expression in a cell, and to induce non-pluripotent cells in pluripotent cells, mixing, cell mammal crib composition and kit
CN102083981A (en) * 2008-04-07 2011-06-01 纽珀滕索有限公司 Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator
KR101661940B1 (en) 2008-05-02 2016-10-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Method of nuclear reprogramming
KR20170078862A (en) 2008-05-16 2017-07-07 타이가 바이오테크놀로지스, 인코포레이티드 Antibodies and processes for preparing the same
CN102725409B (en) 2008-06-13 2016-03-30 怀特黑德生物医学研究所 Cell programming and reprogrammed
CN102083970B (en) 2008-07-21 2014-10-22 泰加生物工艺学公司 Differentiated anucleated cells and method for preparing the same
US8298825B1 (en) * 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
CA2735522C (en) 2008-08-28 2017-04-18 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
WO2010068955A2 (en) 2008-12-13 2010-06-17 Dna Microarray MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING
SG172160A1 (en) 2008-12-17 2011-07-28 Scripps Research Inst Generation and maintenance of stem cells
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
US20120128655A1 (en) * 2009-04-03 2012-05-24 The Mclean Hospital Corporation Induced pluripotent stem cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP2438159B1 (en) 2009-05-29 2018-10-03 Kyoto University Method for selecting clone of induced pluripotent stem cells
JP5751548B2 (en) * 2009-08-07 2015-07-22 国立大学法人京都大学 Canine iPS cells and production method thereof
CN105861446B (en) * 2009-10-16 2021-10-01 斯克里普斯研究所 Induction of pluripotent cells
AU2014250681B2 (en) * 2009-10-16 2016-12-15 The Scripps Research Institute Induction of pluripotent cells
JP2013507974A (en) * 2009-10-29 2013-03-07 マックマスター ユニバーシティー Preparation of induced pluripotent stem cells and progenitor cells from fibroblasts
LT2494039T (en) * 2009-10-31 2019-07-25 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
CN102597221B (en) * 2009-11-04 2015-03-11 细胞动力国际有限公司 Episomal reprogramming with chemicals
US20130189780A1 (en) * 2009-12-31 2013-07-25 Fate Therapeutics, Inc. Reprogramming compositions
US20130059385A1 (en) * 2010-03-02 2013-03-07 The Scripps Research Institute Methods of generating pluripotent stem cells
EP2366432A1 (en) * 2010-03-16 2011-09-21 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto
ES2624780T3 (en) * 2010-03-31 2017-07-17 The Scripps Research Institute Cell reprogramming
CN102260646B (en) * 2010-05-26 2015-09-16 北京瑞普晨创科技有限公司 Prepare a method for induced pluripotent stem cells, test kit and purposes
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
AU2011268056B2 (en) 2010-06-18 2014-04-24 Cellular Dynamics International, Inc. Cardiomyocyte medium with dialyzed serum
WO2012007725A2 (en) * 2010-07-16 2012-01-19 Plasticell Ltd Method of reprogramming a cell
CA2809979A1 (en) 2010-09-01 2012-03-08 Whitehead Institute For Biomedical Research Compositions and methods for modulating emt and uses thereof
WO2012031288A1 (en) * 2010-09-03 2012-03-08 United States Of America As Represented By The Department Of Veterans Affairs Efficient generation of neurally-induced mesenchymal stem cells and applications thereof
EP2616540A4 (en) * 2010-09-14 2014-02-19 Univ Kyoto Method of efficiently establishing induced pluripotent stem cells
CA2849382C (en) * 2010-09-22 2021-02-16 The Regents Of The University Of Colorado, A Body Corporate Therapeutic applications of smad7 for the treatment of oral mucositis
CN103384680B (en) * 2010-12-17 2015-08-26 拜奥拉米那公司 Cell culture medium
CN114164167A (en) 2010-12-22 2022-03-11 菲特治疗公司 Cell culture platform for single cell sorting and enhanced IPSC reprogramming
WO2012090997A1 (en) * 2010-12-27 2012-07-05 京都府公立大学法人 iPS CELLS AND METHOD FOR GENERATING SAME
WO2012098260A1 (en) * 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
ES2957478T3 (en) * 2011-05-02 2024-01-19 Univ Wayne State A protein-induced pluripotent stem cell technology and uses thereof
WO2012166973A1 (en) * 2011-06-01 2012-12-06 Sanford-Burnham Medical Research Institute Methods for promoting cell reprogramming
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
EP2734622B1 (en) * 2011-07-19 2018-09-05 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage
EP2737064B1 (en) 2011-07-25 2017-12-06 Kyoto University Method for screening induced pluripotent stem cells
CN103917641B (en) 2011-10-21 2018-04-27 爱科来株式会社 The cultivation of the single cell dispersion of the maintenance versatility carried out by laminar flow
JP5999658B2 (en) 2011-11-25 2016-09-28 国立大学法人京都大学 Method for culturing pluripotent stem cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
BR112014013664A2 (en) 2011-12-05 2020-11-03 Factor Bioscience Inc. methods and products for transfecting cells
WO2013131000A1 (en) * 2012-03-01 2013-09-06 Whitehead Institute For Biomedical Research Emt-inducing transcription factors cooperate with sox9
JP6445422B2 (en) * 2012-03-14 2018-12-26 ザ チルドレンズ メディカル センター コーポレーション High-throughput image-based chemical screening in zebrafish blastomere cell cultures
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10357517B1 (en) * 2012-10-01 2019-07-23 University Of South Florida Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592
BR122019025678B1 (en) 2012-11-01 2023-04-18 Factor Bioscience Inc COMPOSITIONS COMPRISING NUCLEIC ACID ENCODING A GENE-EDITING PROTEIN
US10130637B2 (en) 2012-11-02 2018-11-20 Duke University Inhibition of histone methyltransferase for cardiac reprogramming
JP6509126B2 (en) * 2013-01-09 2019-05-08 インターナショナル ステム セル コーポレイション Small molecules that promote skin regeneration
US20160002599A1 (en) 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
US9738861B2 (en) 2013-03-06 2017-08-22 Kyoto University Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
US9422352B2 (en) 2013-03-08 2016-08-23 The Regents Of The University Of Colorado, A Body Corporate PTD-SMAD7 therapeutics
US9365825B2 (en) * 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
ES2786925T3 (en) 2013-03-14 2020-10-14 Brigham & Womens Hospital Inc Compositions and Procedures for Epithelial Stem Cell Growth and Expansion
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2014148646A1 (en) 2013-03-21 2014-09-25 国立大学法人京都大学 Pluripotent stem cell for neuronal differentiation induction
JP6473686B2 (en) 2013-03-25 2019-02-20 公益財団法人神戸医療産業都市推進機構 Cell sorting method
KR20140121317A (en) * 2013-04-06 2014-10-15 서울대학교산학협력단 Method for producing induced neural stem cell from non-neuronal cell, and induced neural stem cell produced by the same
CA2909230C (en) 2013-04-12 2021-06-15 Kyoto University Method for inducing alveolar epithelial progenitor cells
JP6429280B2 (en) 2013-05-14 2018-11-28 国立大学法人京都大学 Efficient cardiomyocyte induction method
CN105247041B (en) 2013-05-31 2018-04-20 爱心细胞有限公司 Group enters to have the stacking cell patch of hydrogel
SG11201510201PA (en) 2013-06-11 2016-01-28 Univ Kyoto Method for producing renal progenitor cells and drug comprising the same
CN104278008B (en) * 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 Method, kit and application for preparing pluripotent stem cells through small molecule compound treatment
KR101655383B1 (en) * 2013-07-27 2016-09-08 고려대학교 산학협력단 Composition for Maintaining Chromosome Stability of Pluripotent Stem Cells Comprising Small Molecules
EP3031905A4 (en) 2013-08-07 2017-04-26 Kyoto University Method for producing pancreatic hormone-producing cell
CN105849255A (en) 2013-09-05 2016-08-10 国立大学法人京都大学 New method for inducing dopamine-producing neural precursor cells
CN104419683A (en) * 2013-09-10 2015-03-18 中国科学院生物物理研究所 Method for preparing autologous induced pluripotent stem cells of patient with Fanconi anemia and application of method
WO2015061568A1 (en) * 2013-10-23 2015-04-30 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
CN106170295B (en) 2013-10-25 2020-11-06 韦恩州立大学 Methods, systems, and compositions related to cell transformation by protein-induced in vivo cell reprogramming
EP3064577B1 (en) 2013-11-01 2020-09-09 Kyoto University Novel chondrocyte induction method
US9512406B2 (en) 2013-12-20 2016-12-06 The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone Generating hepatocytes
RU2020104969A (en) 2014-01-31 2020-03-13 Фэктор Байосайенс Инк. METHODS AND PRODUCTS FOR THE PRODUCTION AND DELIVERY OF NUCLEIC ACIDS
CN104894060B (en) * 2014-03-03 2018-11-06 中国科学院上海生命科学研究院 Inducing somatic transdifferentiation is the method and its application of neural stem cell
EP3604499A1 (en) 2014-03-04 2020-02-05 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
JP7012432B2 (en) 2014-07-14 2022-01-28 中外製薬株式会社 Methods for identifying protein epitopes
US20170211091A1 (en) * 2014-07-16 2017-07-27 Fundación Pública Andaluza Progreso Y Salud Methods for generating induced pluripotent stem cells
US20160030484A1 (en) 2014-08-04 2016-02-04 University Of Kansas Mammalian pluripotent stem cells, methods for their production, and uses thereof
RU2565548C1 (en) * 2014-08-05 2015-10-20 Дмитрий Андреевич Журавлёв Method of producing of pluripotent stem cells
EP3177709B1 (en) 2014-08-07 2022-05-18 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reversible stencils for fabricating micro-tissues
CN107073042A (en) * 2014-09-03 2017-08-18 布里格海姆妇女医院公司 Composition, the system and method for hearing loss are treated for producing inner ear hair cells
JP7253692B2 (en) 2014-12-26 2023-04-07 国立大学法人京都大学 Hepatocyte induction method
WO2016117139A1 (en) 2015-01-20 2016-07-28 タカラバイオ株式会社 Method for producing nervous system cells
JP2018504122A (en) 2015-01-26 2018-02-15 フェイト セラピューティクス，インコーポレイテッド Cells with increased immunomodulatory properties and methods for their use and production
EP3250679B1 (en) * 2015-01-30 2020-08-19 Centre National de la Recherche Scientifique (CNRS) Reprogramming method for producing induced pluripotent stem cells (ipsc)
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2016131137A1 (en) 2015-02-17 2016-08-25 University Health Network Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes
JP2016202172A (en) 2015-04-16 2016-12-08 国立大学法人京都大学 Production method of pseudoislet
KR20180033537A (en) 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 PD-L1 expressing hematopoietic stem cells and uses
WO2017033863A1 (en) * 2015-08-21 2017-03-02 京都府公立大学法人 Osteoblasts and method for preparing same
CA3001917A1 (en) * 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
KR20180073631A (en) * 2015-10-21 2018-07-02 교토후고리츠다이가쿠호진 Cell preparation method
WO2017120543A1 (en) 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
CN108779439B (en) * 2016-01-08 2023-05-30 埃维亚生命科学有限公司 Method for preparing hepatic stem cells/precursor cells from mature hepatocytes by using low molecular weight compound
KR20180096707A (en) * 2016-01-20 2018-08-29 페이트 세러퓨틱스, 인코포레이티드 Composition and method for immune cell regulation in adoptive immunotherapy
US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
PL3444334T3 (en) 2016-04-15 2022-01-10 Kyoto University Method for inducing antigen specific cd8 positive t cells
EP3447130A4 (en) 2016-04-22 2019-11-13 Kyoto University Method for producing dopamine-producing neural precursor cells
CN105943526B (en) * 2016-05-18 2018-08-14 上海交通大学医学院附属上海儿童医学中心 Applications of the PD0325901 in maintaining arterial duct to open
JP7005528B2 (en) * 2016-06-03 2022-01-21 中国人民解放軍軍事医学科学院野戦輸血研究所 Combinations, reprogramming methods and applications of low molecular weight compounds for reprogramming gastrointestinal tract-derived epithelial cells into endoderm stem cells / progenitor cells
WO2018005799A1 (en) * 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
JP2019528284A (en) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド Nucleic acid product and method of administration thereof
JP7134416B2 (en) * 2016-10-28 2022-09-12 国立研究開発法人国立がん研究センター Method for preparing human hepatic progenitor cells
IL293611A (en) 2016-12-02 2022-08-01 Taiga Biotechnologies Inc Nanoparticle formulations
WO2018106595A1 (en) 2016-12-05 2018-06-14 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CA3048379A1 (en) 2016-12-27 2018-07-05 Sumitomo Chemical Company, Limited Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells
CN106754655B (en) * 2016-12-29 2020-06-19 赛业（苏州）生物科技有限公司 Animal embryo culture medium
KR20190104359A (en) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 1H-pyrrole-2,5-dione compound and method of using the same for inducing self-renewal of stem / progenitor supporting cells
JP7136454B2 (en) 2017-01-20 2022-09-13 国立大学法人京都大学 Method for producing CD8α+β+ cytotoxic T cells
EP3575392A4 (en) 2017-01-26 2020-08-26 Osaka University Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells
US11559548B2 (en) 2017-03-14 2023-01-24 Kyoto University Method for producing helper T cells from pluripotent stem cells
US11821007B2 (en) 2017-05-25 2023-11-21 Kyoto University Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell
CN111164209A (en) 2017-06-19 2020-05-15 公益财团法人神户医疗产业都市推进机构 Method for predicting differentiation potency of pluripotent stem cell and reagent for use in the prediction method
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US20190062711A1 (en) * 2017-08-25 2019-02-28 So Young Life Sciences Corporation Use Of Phosphorylated TBeta4 And Other Factors To Generate Human Induced Pluripotent Stem Cells
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
WO2019078263A1 (en) 2017-10-17 2019-04-25 国立大学法人京都大学 Method for obtaining artificial neuromuscular junction from pluripotent stem cells
KR101810014B1 (en) 2017-10-23 2018-01-18 차의과학대학교 산학협력단 Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker
KR101810008B1 (en) 2017-10-23 2018-01-18 차의과학대학교 산학협력단 Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents
KR101998633B1 (en) * 2017-10-31 2019-07-11 가톨릭관동대학교산학협력단 Use of ellipticine for inducing differentiation of stem cells into chondrocytes
CN108624562B (en) * 2018-05-18 2021-11-02 首都医科大学附属北京朝阳医院 Method for preparing tumor stem cells and special kit thereof
KR102158783B1 (en) * 2018-06-18 2020-09-22 한국생명공학연구원 Cell reprogramming composition and method for producing an indueced pluripotent stem cell using the same
AU2019302207A1 (en) 2018-07-13 2021-03-04 Kyoto University Method for producing γδ T cells
US20210299331A1 (en) 2018-07-19 2021-09-30 Kyoto University Pluripotent stem cell-derived plate-shaped cartilage and method for producing the same
US20210332329A1 (en) 2018-07-23 2021-10-28 Kyoto University Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP7016102B2 (en) 2018-12-06 2022-02-04 キリンホールディングス株式会社 A method for producing T cells or NK cells, a medium for culturing T cells or NK cells, a method for culturing T cells or NK cells, a method for maintaining an undifferentiated state of undifferentiated T cells, and an agent for promoting the growth of T cells or NK cells.
US20220056413A1 (en) 2018-12-21 2022-02-24 Kyoto University Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
US20220062341A1 (en) 2018-12-26 2022-03-03 Kirin Holdings Kabushiki Kaisha Modified tcr and production method therefor
JPWO2020230832A1 (en) 2019-05-15 2020-11-19
JPWO2020235319A1 (en) 2019-05-20 2020-11-26
WO2021015228A1 (en) * 2019-07-25 2021-01-28 富士フイルム株式会社 Method for producing specific differentiated cells
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN112301052A (en) * 2019-08-01 2021-02-02 浙江霍德生物工程有限公司 Method for preparing induced multifunctional stem cells through somatic cell reprogramming
JP7058431B2 (en) 2019-12-12 2022-04-22 国立大学法人千葉大学 Freeze-dried preparation containing megakaryocytes and platelets
KR102087084B1 (en) * 2020-02-03 2020-03-10 주식회사 이에이치엘바이오 Culture method of adipose-drived stem cell proliferation expressing anti-aging factors
US11801304B2 (en) 2020-02-19 2023-10-31 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
JP2023516632A (en) 2020-02-28 2023-04-20 武田薬品工業株式会社 Method for producing natural killer cells from pluripotent stem cells
EP4170020A1 (en) 2020-06-17 2023-04-26 Kyoto University Chimeric antigen receptor-expressing immunocompetent cells
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
JPWO2022019152A1 (en) 2020-07-20 2022-01-27
JPWO2022039279A1 (en) 2020-08-18 2022-02-24
EP4310176A1 (en) 2021-03-17 2024-01-24 Astellas Pharma Inc. Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein
TW202305112A (en) 2021-04-30 2023-02-01 國立研究開發法人理化學研究所 Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates
CN117413051A (en) 2021-06-04 2024-01-16 麒麟控股株式会社 Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition
EP4353243A1 (en) 2021-06-10 2024-04-17 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
AU2022292988A1 (en) 2021-06-15 2024-01-04 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
WO2023283631A2 (en) * 2021-07-08 2023-01-12 The Broad Institute, Inc. Methods for differentiating and screening stem cells
JPWO2023286832A1 (en) 2021-07-15 2023-01-19
WO2023286834A1 (en) 2021-07-15 2023-01-19 アステラス製薬株式会社 Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level
JPWO2023017848A1 (en) 2021-08-11 2023-02-16
WO2023074648A1 (en) * 2021-10-25 2023-05-04 富士フイルム株式会社 Method for producing intestinal endocrine cells, pluripotent stem cell-derived intestinal endocrine cells, medium or medium kit, and use of the same
CN116694551A (en) * 2022-02-24 2023-09-05 清华大学 Induced mature liver cell and preparation method thereof
CN114702591B (en) * 2022-05-17 2022-09-23 诺赛联合(北京)生物医学科技有限公司 Preparation technology of adult cell-derived organoid
JP7461691B1 (en) 2023-06-23 2024-04-04 株式会社アンプリー Carbon dioxide gas pack kit

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
DE69840497D1 (en) 1997-05-07 2009-03-12 William J Crumb Use of aplidine for the treatment of cardiovascular diseases
JP3626206B2 (en) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Smad6 and its use
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
CA2336220A1 (en) 1998-07-24 2000-02-03 The Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the tgf-.beta. family of growth factors
GB9819912D0 (en) * 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
AU2483000A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Treatment of asthma with mek inhibitors
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
CN1630714A (en) * 2001-09-21 2005-06-22 罗切斯特大学 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
ATE554169T1 (en) 2001-11-02 2012-05-15 Giuliani Int Ltd SMAD7 INHIBITORS FOR THE TREATMENT OF CNS DISEASES
AU2003210405A1 (en) * 2002-03-05 2003-09-16 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
CA2506085A1 (en) 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
JP2006517234A (en) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド Vanilloid receptor ligands and their use in therapy
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
CN103602633A (en) 2003-10-03 2014-02-26 福田惠一 Method of inducing the differentiation of stem cells into myocardial cells
GB2407048B (en) 2003-10-15 2007-07-11 Biotrace Internat Plc Laboratory apparatus
CA2542276A1 (en) 2003-10-16 2005-04-28 The University Court Of The University Of Edinburgh Control of es cell self-renewal and lineage specification, and medium therefor
US20070141703A1 (en) 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
KR20070083559A (en) 2004-08-13 2007-08-24 더 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 Compositions and methods for self-renewal and differentiation in human embryonic stem cells
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
JP4395193B2 (en) * 2005-08-01 2010-01-06 ニューポテンシャル，インコーポレイテッド Production of reprogrammed cells with ability to recover
CA2621161A1 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
CA2627857A1 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2006313518A1 (en) * 2005-11-11 2007-05-18 The University Court Of University Of Edinburgh Reprogramming and genetic modification of cells
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
BRPI0619794B8 (en) * 2005-12-13 2022-06-14 Univ Kyoto Use of a reprogramming factor, agent for preparing an induced pluripotent stem cell from a somatic cell and methods for preparing an induced pluripotent stem cell method and for preparing a somatic cell and use of induced pluripotent stem cells
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
WO2007069686A1 (en) 2005-12-16 2007-06-21 Meidensha Corporation Vacuum capacitor and vacuum valve
GB0601538D0 (en) * 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo Joint use of tgf-beta signal inhibitor and antitumor agent
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP1999249B8 (en) 2006-03-30 2012-02-15 The University Court Of The University of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
GB2452186B (en) 2006-05-02 2011-01-26 Wisconsin Alumni Res Found Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
GB2437737B (en) 2006-05-04 2008-07-09 Access Products Ltd Scaffolding
MX2009000285A (en) 2006-06-30 2009-06-08 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof.
PT2044056E (en) 2006-07-14 2012-12-05 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
JP5419279B2 (en) 2007-01-17 2014-02-19 ウィスコンシン アラムニ リサーチ ファンデーション Improved stem cell culture
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
AU2008211103B2 (en) 2007-01-30 2014-05-08 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC)
KR20090122946A (en) 2007-02-27 2009-12-01 주식회사 프로셀제약 Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells
EP3449923A1 (en) 2007-03-07 2019-03-06 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
CA2684460C (en) * 2007-04-18 2017-01-03 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (en) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
KR20100059789A (en) 2007-06-29 2010-06-04 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Automated method and apparatus for embryonic stem cell culture
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) * 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
CN101617043B (en) 2007-10-31 2014-03-12 国立大学法人京都大学 Nuclear reprogramming method
JP4604076B2 (en) 2007-11-07 2010-12-22 国立大学法人静岡大学 Electrolyte membrane for fuel cell
WO2009073523A2 (en) 2007-11-29 2009-06-11 Children's Hospital Of Orange County De-differentiation of human cells
US20110190729A1 (en) 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
EP2224940A1 (en) 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
WO2009082184A2 (en) 2007-12-26 2009-07-02 Posdata Co., Ltd. Method for determining spurious and wireless communication system applying that method
BRPI0908708A2 (en) 2008-03-17 2019-09-24 Scripps Research Inst methods for producing pluripotent stem cells induced from non-pluripotent mammalian cells, to screen for agents that induce reprogramming or de-differentiation of mammalian cells within pluripotent stem cells, to screen for mammalian cells with pluripotent stem cell characteristics , to induce oct4 expression in a cell and to induce non-pluripotent cells in pluripotent cells, mixing, mammalian cell, methods for producing pluripotent stem cells induced from non-pluripotent mammalian cells, to screen for agents that induce reprogramming or de-differentiating mammalian cells within pluripotent stem cells, to screen for mammalian cells with pluripotent stem cell characteristics, to induce oct4 expression in a cell, and to induce non-pluripotent cells in pluripotent cells, mixing, cell mammal crib composition and kit
US8298825B1 (en) * 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
SG172160A1 (en) 2008-12-17 2011-07-28 Scripps Research Inst Generation and maintenance of stem cells
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
EP2438159B1 (en) 2009-05-29 2018-10-03 Kyoto University Method for selecting clone of induced pluripotent stem cells
JP5376478B2 (en) 2009-08-07 2013-12-25 国立大学法人京都大学 Efficient method for establishing induced pluripotent stem cells
CN105861446B (en) 2009-10-16 2021-10-01 斯克里普斯研究所 Induction of pluripotent cells
CN102844428B (en) 2010-03-05 2015-09-02 德克萨斯心脏研究所 ETS2 and MESP1 generates cardiac progenitor cell by inoblast
ES2624780T3 (en) 2010-03-31 2017-07-17 The Scripps Research Institute Cell reprogramming
JO3421B1 (en) 2011-06-20 2019-10-20 H Lundbeck As Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation

Also Published As

Publication number Publication date
SG10202103401QA (en) 2021-05-28
SG188904A1 (en) 2013-04-30
US9534205B2 (en) 2017-01-03
US20110110899A1 (en) 2011-05-12
JP6899792B2 (en) 2021-07-07
IL208144B (en) 2018-10-31
CN102027105B (en) 2015-03-11
RU2010139426A (en) 2012-04-27
JP2011517560A (en) 2011-06-16
KR101679082B1 (en) 2016-11-23
US9771563B2 (en) 2017-09-26
EP2279243A2 (en) 2011-02-02
US9394524B2 (en) 2016-07-19
WO2009117439A3 (en) 2009-12-30
JP6321733B2 (en) 2018-05-09
US20180002671A1 (en) 2018-01-04
US20130273536A1 (en) 2013-10-17
KR20100124335A (en) 2010-11-26
JP2021143194A (en) 2021-09-24
AU2009225665A1 (en) 2009-09-24
US20100267141A1 (en) 2010-10-21
US9068170B2 (en) 2015-06-30
JP2023101613A (en) 2023-07-21
EP2955222A1 (en) 2015-12-16
ES2690554T3 (en) 2018-11-21
EP2279243A4 (en) 2011-06-29
JP2015119714A (en) 2015-07-02
US20100233804A1 (en) 2010-09-16
US20160369244A1 (en) 2016-12-22
US9540615B2 (en) 2017-01-10
HK1151559A1 (en) 2012-02-03
CA2718904A1 (en) 2009-09-24
EP2955222B1 (en) 2018-09-12
JP5951254B2 (en) 2016-07-13
ZA201006683B (en) 2011-11-30
AU2009225665B9 (en) 2015-01-15
EP2279243B1 (en) 2016-01-06
JP7286710B2 (en) 2023-06-05
US9926533B2 (en) 2018-03-27
MX2010010165A (en) 2010-11-25
WO2009117439A2 (en) 2009-09-24
US20170081640A1 (en) 2017-03-23
HK1209457A1 (en) 2016-04-01
CA2718904C (en) 2017-01-03
CN102027105A (en) 2011-04-20
JP2016185172A (en) 2016-10-27
CN104694570A (en) 2015-06-10
US20180171303A1 (en) 2018-06-21
EP3409762A1 (en) 2018-12-05
SG10201607710UA (en) 2016-11-29
JP2018104473A (en) 2018-07-05
BRPI0908708A2 (en) 2019-09-24
AU2009225665B2 (en) 2014-12-04
IL208144A0 (en) 2010-12-30
CN104694570B (en) 2019-07-16

Similar Documents

Publication Publication Date Title
SG10201808863UA (en) Combined chemical and genetic approaches for generation of induced pluripotent stem cells
MX356756B (en) Pluripotent stem cell culture on micro-carriers.
IN2014DN10996A (en)
MX2010000348A (en) Single pluripotent stem cell culture.
SG196784A1 (en) Stem cell cultures
EP2896690A3 (en) Use of RNA for reprogramming somatic cells
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
WO2012021632A3 (en) Generation and use of pluripotent stem cells
WO2008148105A8 (en) Endometrial stem cells and methods of making and using same
WO2010129294A3 (en) Small molecules supporting pluripotent cell growth and methods thereof
SG195299A1 (en) Expansion of stem cells in hollow fiber bioreactors
EP2373784A4 (en) Generation and maintenance of stem cells
EA200870046A1 (en) NUCLEAR REPROGRAMMING FACTOR
EP2633036A4 (en) Differentiation methods for production of glial cell populations
MY159971A (en) Multipotent/pluripotent cells and methods
BR112014031424A2 (en) pluripotent cell treatment
IL214529A0 (en) Bioreactor for the cultivation of mammalian cells and methods of use thereof
IL194828A (en) Method of culturing pluripotent stem cells to produce cells of the endoderm and pancreatic lineage
MX344970B (en) Cell culture medium for adamts protein expression.
EP2548950A3 (en) Reprogramming T cells and hematopoietic cells
WO2011021194A3 (en) Pericyte progenitor cells and methods of generating and using same
WO2012064606A3 (en) Tissue-specific extracellular matrix with or without tissue protein components for cell culture
IN2012DN00852A (en)
WO2010022194A3 (en) Compositions and methods for generation of pluripotent stem cells
WO2006130504A3 (en) Methods for identifying ligands for stem cells and cells derived therefrom